2023-01-26 00:30:00

Latest Clinical Data of InnoCare's Gunagratinib Presented at 2023 ASCO GI

Logo Benzinga
Benzinga
By Business Wire

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the development of therapies for cancer and autoimmune diseases, announced today that the latest clinical result of FGFR inhibitor gunagratinib (ICP-192) for the treatment of cholangiocarcinoma was presented at 2023 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium.

The study was presented in a poster entitled "Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study". Abstract number is 572.

As of September 5, 2022, 18 cholangiocarcinoma patients were treated orally with gunagratinib 20 mg QD. The median age of the patients was 52 with 44.4% male. Among 17 patients who have completed at least one tumor assessment, the overall response rate (ORR) was 52.9%, the disease control rate (DCR) was 94.1% and median progression free survival (mPFS) was 6.93 months (not reached at cutoff). Gunagratinib showed a well-tolerated safety profile.

Continue read on benzinga.com

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-25 08:30:00
Data demonstrates that STC-15, an oral METTL3 inhibitor, exhibits efficacy as a single agent and in combination with venetoclax using patient-derived tumor...

Logo PR Newswire
HealthPress Release2023-01-25 08:30:00
Data demonstrates that STC-15, an oral METTL3 inhibitor, exhibits efficacy as a single agent and in combination with venetoclax using patient-derived tumor...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:00:00
AGOURA HILLS, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical stage...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-05 05:25:00
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today...

Logo GlobeNewswire
SciencePress Release2023-01-25 12:00:00
TNG908 granted Orphan Drug Designation in U.S. for the treatment of malignant glioma BOSTON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc....

Logo Benzinga
Business / FinanceBy Business Wire2023-01-25 11:45:00
Merck MRK, known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 KEYNOTE-966 trial. In the final analysis...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:00:00
First Immunosynthen ADC product candidate enters the clinic CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 12:45:00
Phase 1/2 clinical trial expected to launch in early 2023 and will evaluate safety and preliminary impact on disease activity of IMPT-314 WEST HILLS, Calif.,...

Logo Nasdaq
Business / FinanceBy Rtt News2023-01-25 13:14:19
(RTTNews) - Tango Therapeutics, Inc. (TNGX) Wednesday announced FDA clearance for its Investigational New Drug or IND application for TNG462, a...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:30:00
Preclinical Efficacy and Safety Results Indicate AlloCAR TDevelopment Candidate Controls Tumor Growth without Off-Tumor/Normal Tissue Toxicity SOUTH SAN...

Logo GlobeNewswire
SciencePress Release2023-01-25 12:45:00
Boca Raton, Florida, Jan. 25, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the Company), a clinical-stage immunology company focused on...

Logo PR Newswire
HealthPress Release2023-01-25 11:15:00
Collaboration seeks to improve outcomes for patients with EGFR-positive non-small cell lung cancer WASHINGTON, Jan. 25, 2023 /PRNewswire/ -- LUNGevity...

Logo GlobeNewswire
HealthPress Release2023-01-25 12:00:00
TORONTO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Theralase Technologies Inc. ( Theralase or the Company ) ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage...

Logo GlobeNewswire
SciencePress Release2023-01-25 21:05:00
CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA) today announced that the latest participant dosed at the Cohort 3...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:37:00
Nes-Ziona, Israel, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage macrophage reprogramming...

Logo EIN Presswire
SAINT LOUIS, MISSOURI, USA, January 24, 2023 / EINPresswire.com / -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and...

Logo PR Newswire
HealthPress Release2023-01-25 16:26:00
Policy-minded health care providers band together to support patients with rare, chronic condition called IgG4-RD WASHINGTON, Jan. 25, 2023 /PRNewswire/ -- A...

Logo PR Newswire
HealthPress Release2023-01-25 13:27:00
Patient Recruitment Underway NEW YORK, Jan. 25, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company,...

Logo PR Newswire
HealthPress Release2023-01-25 11:30:00
NEW YORK, Jan. 25, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral...

Logo PR Newswire
HealthPress Release2023-01-25 11:15:00
Collaboration seeks to leverage studies of common drug-resistance mechanisms to improve outcomes for patients with oncogene-driven lung adenocarcinoma...